The pulmonary drug delivery devices market size has grown strongly in recent years. It will grow from $52.8 billion in 2025 to $56.49 billion in 2026 at a compound annual growth rate (CAGR) of 7%. The growth in the historic period can be attributed to increasing prevalence of respiratory diseases, rising use of inhalation therapies, expansion of asthma and copd treatment programs, improvements in inhaler design technologies, growing awareness of pulmonary drug delivery.
The pulmonary drug delivery devices market size is expected to see strong growth in the next few years. It will grow to $71.9 billion in 2030 at a compound annual growth rate (CAGR) of 6.2%. The growth in the forecast period can be attributed to increasing demand for personalized respiratory therapies, rising adoption of digital health integrated inhalers, expansion of home-based respiratory care, growing focus on non-invasive drug delivery, continued innovation in inhalation technologies. Major trends in the forecast period include increasing adoption of smart and connected inhaler devices, rising demand for targeted pulmonary drug delivery, growing use of mesh and ultrasonic nebulizers, expansion of combination drug-device products, enhanced focus on patient adherence.
The rising prevalence of respiratory disorders is expected to drive the growth of the pulmonary drug delivery devices market moving forward. Respiratory disorders are conditions that affect the lungs and airways, impairing normal respiration. The prevalence of these disorders is increasing due to factors such as higher levels of air pollution, rising smoking rates, urbanization, climate change, and an aging population. Pulmonary drug delivery devices are crucial in managing respiratory disorders, as they enable direct delivery of medications to the lungs for faster and more effective treatment. For instance, in May 2025, according to the US National Center for Health Statistics (via the CDC), the age-adjusted prevalence of diagnosed COPD among adults aged 18 and older in 2023 was 3.8 percent, reflecting an upward trend from previous years. Therefore, the increasing prevalence of COPD is driving the growth of the pulmonary drug delivery devices market.
Major companies in the pulmonary drug delivery devices market are developing innovative products, such as small-volume nebulizers, to better serve customers with advanced features. A small-volume nebulizer (SVN) is a medical device used to deliver liquid medication in the form of an aerosolized mist to patients with respiratory conditions such as asthma, chronic obstructive pulmonary disease (COPD), or cystic fibrosis. For instance, in May 2024, Medline Industries, LP, a US-based healthcare company, launched the Hudson RCI TurboMist small-volume nebulizer. This groundbreaking device is designed to deliver medication treatments quickly, in as little as three minutes. The innovative nebulizer can dispense 2.5 times more medication per minute compared to standard nebulizers, reducing treatment times by about 70%. This increase in medication delivery significantly reduces treatment times, benefiting healthcare providers by optimizing patient throughput and enhancing the patient experience by shortening the duration of therapy sessions.
In January 2025, Molex LLC, a US-based electronics and manufacturing company, acquired Vectura Group Ltd. for an undisclosed amount. Through this acquisition, Phillips Medisize, Molex’s contract development and manufacturing arm (CDMO), strengthened its inhalation drug‑delivery capabilities, enabling an expanded portfolio of combination products and device development. Vectura Group Ltd. is a UK-based pharmaceutical technology company specializing in pulmonary drug delivery devices.
Major companies operating in the pulmonary drug delivery devices market are Medtronic plc, Air Liquide S.A., Becton Dickinson And Company, Koninklijke Philips N.V., Medline Industries Inc., ResMed Inc., Drägerwerk AG And Co. KGaA, Smiths Group plc, AptarGroup Inc., Chiesi Farmaceutici S.p.A., Teleflex Incorporated, Fisher And Paykel Healthcare Limited, Invacare Corporation, Vyaire Medical Inc., Inogen Inc., Drive DeVilbiss Healthcare Inc., Hovione, Hamilton Medical AG, GaleMed Corporation, Allied Healthcare Products Inc., Precision Medical Inc., Salter Labs Inc.
North America was the largest region in the pulmonary drug delivery devices market in 2025. The regions covered in the pulmonary drug delivery devices market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the pulmonary drug delivery devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the pulmonary drug delivery devices market by increasing costs of imported plastics, electronic sensors, microvalves, drug canisters, and precision molding equipment used in inhalers and nebulizers. Pharmaceutical and medical device manufacturers in North America and Europe are most affected due to reliance on imported components, while Asia-Pacific faces cost pressure on large-scale device manufacturing. These tariffs are raising device prices and affecting market accessibility. However, they are also promoting regional manufacturing, local component sourcing, and innovation in cost-effective and reusable pulmonary delivery systems.
The pulmonary drug delivery devices market research report is one of a series of new reports that provides pulmonary drug delivery devices market statistics, including pulmonary drug delivery devices industry global market size, regional shares, competitors with a pulmonary drug delivery devices market share, detailed pulmonary drug delivery devices market segments, market trends and opportunities, and any further data you may need to thrive in the pulmonary drug delivery devices industry. This pulmonary drug delivery devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Pulmonary drug delivery devices are inhalation devices designed to administer medications directly to the lungs. These devices enable targeted drug delivery for treating respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). Additionally, pulmonary delivery allows for the systemic absorption of drugs such as insulin and pain medications.
The primary types of pulmonary drug delivery devices include dry powder inhalers, metered dose inhalers, and nebulizers. Dry powder inhalers dispense a measured dose of medication in a fine, dry powder form that the patient inhales directly into their lungs. These devices are used for conditions such as asthma, cystic fibrosis, chronic obstructive pulmonary disease, and others. They are distributed through channels such as retail pharmacies, hospital pharmacies, and e-commerce.
The pulmonary drug delivery devices market consists of sales of jet nebulizers, ultrasonic wave nebulizers, and vibrating mesh nebulizers. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The pulmonary drug delivery devices market size is expected to see strong growth in the next few years. It will grow to $71.9 billion in 2030 at a compound annual growth rate (CAGR) of 6.2%. The growth in the forecast period can be attributed to increasing demand for personalized respiratory therapies, rising adoption of digital health integrated inhalers, expansion of home-based respiratory care, growing focus on non-invasive drug delivery, continued innovation in inhalation technologies. Major trends in the forecast period include increasing adoption of smart and connected inhaler devices, rising demand for targeted pulmonary drug delivery, growing use of mesh and ultrasonic nebulizers, expansion of combination drug-device products, enhanced focus on patient adherence.
The rising prevalence of respiratory disorders is expected to drive the growth of the pulmonary drug delivery devices market moving forward. Respiratory disorders are conditions that affect the lungs and airways, impairing normal respiration. The prevalence of these disorders is increasing due to factors such as higher levels of air pollution, rising smoking rates, urbanization, climate change, and an aging population. Pulmonary drug delivery devices are crucial in managing respiratory disorders, as they enable direct delivery of medications to the lungs for faster and more effective treatment. For instance, in May 2025, according to the US National Center for Health Statistics (via the CDC), the age-adjusted prevalence of diagnosed COPD among adults aged 18 and older in 2023 was 3.8 percent, reflecting an upward trend from previous years. Therefore, the increasing prevalence of COPD is driving the growth of the pulmonary drug delivery devices market.
Major companies in the pulmonary drug delivery devices market are developing innovative products, such as small-volume nebulizers, to better serve customers with advanced features. A small-volume nebulizer (SVN) is a medical device used to deliver liquid medication in the form of an aerosolized mist to patients with respiratory conditions such as asthma, chronic obstructive pulmonary disease (COPD), or cystic fibrosis. For instance, in May 2024, Medline Industries, LP, a US-based healthcare company, launched the Hudson RCI TurboMist small-volume nebulizer. This groundbreaking device is designed to deliver medication treatments quickly, in as little as three minutes. The innovative nebulizer can dispense 2.5 times more medication per minute compared to standard nebulizers, reducing treatment times by about 70%. This increase in medication delivery significantly reduces treatment times, benefiting healthcare providers by optimizing patient throughput and enhancing the patient experience by shortening the duration of therapy sessions.
In January 2025, Molex LLC, a US-based electronics and manufacturing company, acquired Vectura Group Ltd. for an undisclosed amount. Through this acquisition, Phillips Medisize, Molex’s contract development and manufacturing arm (CDMO), strengthened its inhalation drug‑delivery capabilities, enabling an expanded portfolio of combination products and device development. Vectura Group Ltd. is a UK-based pharmaceutical technology company specializing in pulmonary drug delivery devices.
Major companies operating in the pulmonary drug delivery devices market are Medtronic plc, Air Liquide S.A., Becton Dickinson And Company, Koninklijke Philips N.V., Medline Industries Inc., ResMed Inc., Drägerwerk AG And Co. KGaA, Smiths Group plc, AptarGroup Inc., Chiesi Farmaceutici S.p.A., Teleflex Incorporated, Fisher And Paykel Healthcare Limited, Invacare Corporation, Vyaire Medical Inc., Inogen Inc., Drive DeVilbiss Healthcare Inc., Hovione, Hamilton Medical AG, GaleMed Corporation, Allied Healthcare Products Inc., Precision Medical Inc., Salter Labs Inc.
North America was the largest region in the pulmonary drug delivery devices market in 2025. The regions covered in the pulmonary drug delivery devices market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the pulmonary drug delivery devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the pulmonary drug delivery devices market by increasing costs of imported plastics, electronic sensors, microvalves, drug canisters, and precision molding equipment used in inhalers and nebulizers. Pharmaceutical and medical device manufacturers in North America and Europe are most affected due to reliance on imported components, while Asia-Pacific faces cost pressure on large-scale device manufacturing. These tariffs are raising device prices and affecting market accessibility. However, they are also promoting regional manufacturing, local component sourcing, and innovation in cost-effective and reusable pulmonary delivery systems.
The pulmonary drug delivery devices market research report is one of a series of new reports that provides pulmonary drug delivery devices market statistics, including pulmonary drug delivery devices industry global market size, regional shares, competitors with a pulmonary drug delivery devices market share, detailed pulmonary drug delivery devices market segments, market trends and opportunities, and any further data you may need to thrive in the pulmonary drug delivery devices industry. This pulmonary drug delivery devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Pulmonary drug delivery devices are inhalation devices designed to administer medications directly to the lungs. These devices enable targeted drug delivery for treating respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). Additionally, pulmonary delivery allows for the systemic absorption of drugs such as insulin and pain medications.
The primary types of pulmonary drug delivery devices include dry powder inhalers, metered dose inhalers, and nebulizers. Dry powder inhalers dispense a measured dose of medication in a fine, dry powder form that the patient inhales directly into their lungs. These devices are used for conditions such as asthma, cystic fibrosis, chronic obstructive pulmonary disease, and others. They are distributed through channels such as retail pharmacies, hospital pharmacies, and e-commerce.
The pulmonary drug delivery devices market consists of sales of jet nebulizers, ultrasonic wave nebulizers, and vibrating mesh nebulizers. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Pulmonary Drug Delivery Devices Market Characteristics
3. Pulmonary Drug Delivery Devices Market Supply Chain Analysis
4. Global Pulmonary Drug Delivery Devices Market Trends and Strategies
5. Pulmonary Drug Delivery Devices Market Analysis of End Use Industries
7. Global Pulmonary Drug Delivery Devices Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Pulmonary Drug Delivery Devices Total Addressable Market (TAM) Analysis for the Market
9. Pulmonary Drug Delivery Devices Market Segmentation
10. Pulmonary Drug Delivery Devices Market Regional and Country Analysis
11. Asia-Pacific Pulmonary Drug Delivery Devices Market
12. China Pulmonary Drug Delivery Devices Market
13. India Pulmonary Drug Delivery Devices Market
14. Japan Pulmonary Drug Delivery Devices Market
15. Australia Pulmonary Drug Delivery Devices Market
16. Indonesia Pulmonary Drug Delivery Devices Market
17. South Korea Pulmonary Drug Delivery Devices Market
18. Taiwan Pulmonary Drug Delivery Devices Market
19. South East Asia Pulmonary Drug Delivery Devices Market
20. Western Europe Pulmonary Drug Delivery Devices Market
21. UK Pulmonary Drug Delivery Devices Market
22. Germany Pulmonary Drug Delivery Devices Market
23. France Pulmonary Drug Delivery Devices Market
24. Italy Pulmonary Drug Delivery Devices Market
25. Spain Pulmonary Drug Delivery Devices Market
26. Eastern Europe Pulmonary Drug Delivery Devices Market
27. Russia Pulmonary Drug Delivery Devices Market
28. North America Pulmonary Drug Delivery Devices Market
29. USA Pulmonary Drug Delivery Devices Market
30. Canada Pulmonary Drug Delivery Devices Market
31. South America Pulmonary Drug Delivery Devices Market
32. Brazil Pulmonary Drug Delivery Devices Market
33. Middle East Pulmonary Drug Delivery Devices Market
34. Africa Pulmonary Drug Delivery Devices Market
36. Pulmonary Drug Delivery Devices Market Competitive Landscape and Company Profiles
37. Pulmonary Drug Delivery Devices Market Other Major and Innovative Companies
40. Pulmonary Drug Delivery Devices Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
Pulmonary Drug Delivery Devices Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses pulmonary drug delivery devices market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for pulmonary drug delivery devices? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The pulmonary drug delivery devices market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Product Type: Dry Powder Inhalers; Metered Dose Inhalers; Nebulizers2) By Application: Asthma; Cystic Fibrosis; Chronic Obstructive Pulmonary Disease; Other Applications
3) By Distribution Channel: Retail Pharmacies; Hospital Pharmacies; E-Commerce
Subsegments:
1) By Dry Powder Inhalers (DPIs): Single-Dose DPIs; Multi-Dose DPIs2) By Metered Dose Inhalers (MDIs): CFC-Based MDIs; HFA-Based MDIs
3) By Nebulizers: Jet Nebulizers; Ultrasonic Nebulizers; Mesh Nebulizers
Companies Mentioned: Medtronic plc; Air Liquide S.A.; Becton Dickinson And Company; Koninklijke Philips N.V.; Medline Industries Inc.; ResMed Inc.; Drägerwerk AG And Co. KGaA; Smiths Group plc; AptarGroup Inc.; Chiesi Farmaceutici S.p.A.; Teleflex Incorporated; Fisher And Paykel Healthcare Limited; Invacare Corporation; Vyaire Medical Inc.; Inogen Inc.; Drive DeVilbiss Healthcare Inc.; Hovione; Hamilton Medical AG; GaleMed Corporation; Allied Healthcare Products Inc.; Precision Medical Inc.; Salter Labs Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Pulmonary Drug Delivery Devices market report include:- Medtronic plc
- Air Liquide S.A.
- Becton Dickinson And Company
- Koninklijke Philips N.V.
- Medline Industries Inc.
- ResMed Inc.
- Drägerwerk AG And Co. KGaA
- Smiths Group plc
- AptarGroup Inc.
- Chiesi Farmaceutici S.p.A.
- Teleflex Incorporated
- Fisher And Paykel Healthcare Limited
- Invacare Corporation
- Vyaire Medical Inc.
- Inogen Inc.
- Drive DeVilbiss Healthcare Inc.
- Hovione
- Hamilton Medical AG
- GaleMed Corporation
- Allied Healthcare Products Inc.
- Precision Medical Inc.
- Salter Labs Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 56.49 Billion |
| Forecasted Market Value ( USD | $ 71.9 Billion |
| Compound Annual Growth Rate | 6.2% |
| Regions Covered | Global |
| No. of Companies Mentioned | 23 |
